Keytruda combination therapy for gastric cancer Murshadon reaches clinical trial partnership

Under the terms of the agreement, Dinghang Pharma will conduct a one-arm open label Phase 2 clinical study aimed at evaluating the effectiveness and safety of the combination therapy for patients with advanced gastric cancer and esophageal gastric combination cancer who have undergone at least one failed pre-treatmentThe study is expected to begin in the second half of 2019, recruiting about 80 patientsBavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS)PS is phospholipid exposed to the surface of stress cells in tumors and their substratesBavituximab blocks the binding of PS with a variety of immune cell receptors, including TIM and TAM, reversing the PS-mediated immunosuppression processThere have been trials that have shown that PS-targeted antibodies can alter the function of immune cells in tumors and stimulate the performance of multiple immune activation sororiasis and antitumor immune responsesThis mechanism can also allow other cancer therapies to attack tumors more effectively and without restrictionImportantly, bavituximab has demonstrated its controlled safety and tolerance in clinical trials completed to dateThe PS on the surface of thecell is an immune checkpoint (Image Source: References)Keytruda is a human-derived PD-1 monoclonal antibody that blocks the binding of the PD-1 receptor on the surface of T cells to its ligand, activating the T-cell and allowing it to attack the tumorThe weight-heavy therapy has been expanding its indications since it was approved for the treatment of melanoma in 2014note: The original text has a limitationReferences:, Oncology, IncAnnounces Clinical Trial Collaboration Merck to Evaluate Bavituximab in Combination with KEYTRUDa ® (Pembrolizumab) in Advanced Gastrior Gastroeal Cancer Retrieved Aug 12, 2019, from Retrieved Aug 12, 2019 from